glp-1 and parkinson's disease A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes obesity, including cardiovascular and neurodegenerative disorders The critical role of GLP-1

Tirzepatide's SURMOUNT-5 head-to-head vs semaglutide (2025): Zepbound demonstrated 47% greater relative weight loss vs Wegovy in a direct Phase 3b comparison the most commercially significant clinical trial result in the obesity market, directly challenging Novo Nordisk's market leadership

The TGR inhibitors, reported herein, are schistosomicidal both ex vivo and in vivo

The importance of lab testing Lab testing plays an important role in guiding your B12 treatments

Regular check-ins help track progress and make sure the medication continues to support your overall health

We encourage anyone considering medical weight loss to engage in open dialogue with their healthcare team

The information presented in this activity is not meant to serve as a guideline for patient management